Everything below concerns Lactam bridge. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-06. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Primary receptor family | Melanocortin (MC1 to MC5) | Agonist activity reported at several subtypes |
| Signalling pathway | Gs, adenylyl cyclase, cyclic AMP | Canonical melanocortin signalling route |
| Backbone length | Seven amino acids | Classified as a cyclic heptapeptide |
| Ring closure | Lactam bridge | Constrains conformation and resists peptidases |
| Terminal modifications | Acetylated N-terminus, amidated C-terminus | Reduces breakdown by exopeptidases |
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Methenamine, also known as 1,3,5,7-tetraazaadamantane, is a simple cyclic hydrocarbon with a cage-like structure and is similar in structure to adamantane (tricyclo[3.3.1.13,7]decane). It is specifically the analogue of adamantane in which the carbon atoms at the 1, 3, 4, and 7 positions have been replaced with nitrogen atoms. The drug is a white or colorless and odorless crystalline compound with a sweet, sour, and/or metallic taste. It is a hydrophilic compound with a predicted log P (XLogP3) of 0.3. Methenamine is usually provided medically as the hippuric acid or mandelic acid salt. Methenamine is the cation and hippuric acid or mandelic acid is the anion.
=== 547th Grenadier Division === The division was created as the 547th Grenadier Division in Military District V (Stuttgart) as a so-called Sperrdivision ("blocking division") belonging to the 29th Aufstellungswelle ("Wave of formations"). It was scheduled to be formed on 11 July 1944, however, its actual formation took place on 27 July 1944. From August 1944, the division served with the 4th Army under Army Group Centre and fought in Lithuania. On 9 October 1944, the 547th Grenadier Division was redesignated as the 547th Volksgrenadier Division. The reorganization was intended to bring the unit up to the standard of a division belonging to the 32nd wave of formations.
Mephedrone acts as a potent substrate for monoamine transporters, including the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET). It inhibits the reuptake of these neurotransmitters and promotes their release. The drug induces a rapid and significant increase in extracellular levels of dopamine, serotonin, and norepinephrine. This effect is more pronounced for serotonin compared to dopamine, which distinguishes mephedrone from much of the other psychostimulants. The pharmacodynamic profile of mephedrone is often compared to MDMA and methamphetamine. Like MDMA, it has a greater effect on serotonin than dopamine release. Similar to methamphetamine, it causes rapid dopamine release. Mephedrone has been found to be a full releaser of serotonin but a partial releaser of dopamine. In addition to induction of monoamine release via the monoamine transporters, mephedrone shows significant affinity for various receptors, including the serotonin 5-HT2A, 5-HT2B, 5-HT2C, and α2-adrenergic receptors, as well as the trace amine-associated receptor 1 (TAAR1). Mephedrone is a potent and near-full agonist of the serotonin 5-HT2A receptor, whereas it was inactive as an agonist of the serotonin 5-HT2B receptor. Mephedrone binds to and activates the rat and mouse TAAR1 with micromolar potencies, but is not an agonist of the human TAAR1 (EC50Tooltip half-maximal effective concentration > 30 μM).
Anne-Claude Gingras is a senior investigator at Lunenfeld-Tanenbaum Research Institute, and a professor in the department of molecular genetics at the University of Toronto. She is an expert in mass spectrometry based proteomics technology that allows identification and quantification of protein from various biological samples. Gingras was born on Île d'Orléans, Quebec. She earned her undergraduate degree at Université Laval in Quebec. She completed her PhD in biochemistry at McGill University in Montreal, studying how 4E-BP1 regulated translation initiation, under the mentorship of Nahum Sonenberg. After graduating in 2001, she began postdoctoral research in Seattle at the Institute for Systems Biology in the lab of Ruedi Aebersold, where she studied proteomics for three years. In 2005, Gingras moved to Toronto and joined the Lunenfeld-Tanenbaum Research Institute, and in 2006, she began teaching at the University of Toronto in the department of molecular genetics.
Sources: en.wikipedia.org
Iodine-131 (131I, I-131) is a radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley. It has a radioactive decay half-life of about eight days. It is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production. It also plays a major role as a radioactive isotope present in nuclear fission products, and was a significant contributor to the health hazards from open-air atomic bomb testing in the 1950s, and from the Chernobyl disaster, as well as being a large fraction of the contamination hazard in the first weeks in the Fukushima nuclear crisis. This is because 131I is a major fission product of uranium and plutonium, comprising nearly 3% of the total products of fission (see fission product yield). Due to its beta decay, iodine-131 causes mutation and death in cells that it penetrates, and other cells up to several millimeters away. For this reason, high doses of the isotope are sometimes less dangerous than low doses, since they tend to kill thyroid tissues that would otherwise become cancerous as a result of the radiation. For example, children treated with moderate dose of 131I for thyroid adenomas had a detectable increase in thyroid cancer, but children treated with a much higher dose did not. Likewise, most studies of very-high-dose 131I for treatment of Graves' disease have failed to find any increase in thyroid cancer, even though there is linear increase in thyroid cancer risk with 131I absorption at moderate doses.
== First round proper == The first round saw the 32 winners from the fourth qualifying round joined by the 48 clubs from League One and League Two. The draw was made on 17 October 2022 by Dion Dublin and Alan Smith on BBC Two, during a live broadcast from Alvechurch. The round included six teams from the seventh tier, the lowest-ranked teams remaining in the competition: Alvechurch, Bracknell Town, Coalville Town, Merthyr Town, Needham Market, and South Shields.
Sandra Jill James is a retired American biochemist and autism researcher who studied metabolic autism biomarkers. She worked at Arkansas Children's Hospital Research Institute, where she was the director of the Metabolic Genomics Laboratory, as well as the University of Arkansas for Medical Sciences' department of pediatrics, where she began working in 2002. She was also a member of the Autism Speaks Treatment Advisory Board. James' research focused on the role of epigenetics in autism, as well as the effectiveness of supplements as a treatment for autism and the potential existence of abnormal metabolism in autistic children. This research was previously funded by a 5-year grant from the National Institutes of Health entitled "Metabolic biomarkers of autism: predictive potential and genetic susceptibility", as well as by a grant from Autism Speaks. James has falsely speculated that the thiomersal used as a preservative in some vaccines is potentially harmful to the human brain and that prophylactic supplements may protect against such harm preceding vaccination.
Sources: en.wikipedia.org
For this reason, certain methods construct a background tree using 16S rRNA sequences which they use as the canonical tree of life. The distance matrix constructed from this tree of life is then subtracted from the distance matrices of the proteins of interest. However, because RNA distance matrices and DNA distance matrices have different scale, presumably because RNA and DNA have different mutation rates, the RNA matrix needs to be rescaled before it can be subtracted from the DNA matrices. By using molecular clock proteins, the scaling coefficient for protein distance/RNA distance can be calculated. This coefficient is used to rescale the RNA matrix.
Boston Market Corporation, known as Boston Chicken until 1995, is an American fast casual restaurant chain headquartered in Newtown Township, Pennsylvania. Since 2020, it has been owned by Engage Brands, LLC, a company of Rohan Group. From 1985 to 1995, Boston Market was known as Boston Chicken, which rapidly expanded to over a thousand locations. By the late 1990s, the chain filed for bankruptcy and closed many stores until a few hundred remained. McDonald's purchased the chain in 2000. It was sold again in 2007, then in 2020. As of November 2020, the chain had approximately 342 company-owned restaurant locations in 28 states and Puerto Rico. In the 2020s the chain encountered legal troubles and went into a rapid decline to end 2024 with only 16 remaining stores. At its peak, Boston Market had its greatest presence in the Northeastern and Midwestern United States, as well as California, Florida, and Texas. Boston Market helped popularize rotisserie chicken and fast-casual dining, both of which remain popular nationally. While initially specializing in rotisserie chicken, the chain later branched out into other meats, including turkey, meatloaf, and ham. A typical meal paired a protein with sides like potatoes, creamed spinach, or mac & cheese, accompanied by a piece of corn bread. Stores also offered seasonal specials and sandwiches. Frozen meals and side dishes continue to be sold nationally under the Boston Market brand name in food markets.
== Research == The International Society of Antimicrobial Chemotherapy (ISAC) is one of the major umbrella organizations for education, research and development in the area of therapy of infections. Its members are national organizations, currently 86 and over 50,000 individual members.
Sources: en.wikipedia.org
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.
The lactam bridge locks the peptide into a defined shape and makes it harder for peptidases to cut the backbone. Terminal blocking groups add further protection at both ends. Together these features extend the molecule's persistence in circulation compared with linear peptides.
Evidence from animals favors hypothalamic melanocortin circuits, yet direct confirmation in humans is lacking. A peripheral vascular contribution has also been proposed. How receptor binding translates into a reported behavioral effect is still not mapped.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.